抗癌藥物市場：依藥物類別、適應症和地區分類

Cancer Drugs Market, By Drug Class Type and By Indication By Geography

出版日期: 2025年03月26日 | 出版商:

Coherent Market Insights | 英文 150 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計 2025 年腫瘤藥物市場規模為 1,787.6 億美元，到 2032 年將達到 2,985.1 億美元，2025 年至 2032 年的年複合成長率（CAGR）為 7.6%。

報告範圍		報告詳細資訊
基準年	2024	2025年的市場規模	1787.6億美元
效能數據	2020-2024	預測期	2025-2032
預測期間：2025年至2032年的複合年成長率	7.60%	2032年價值預測	2985.1億美元

癌症是一種極度致命的疾病，患者身體某部位的細胞會不受控制地生長並擴散到身體的其他部位。化療、荷爾蒙療法、標靶抗癌藥物、免疫療法藥物和雙磷酸鹽等抗癌藥物被用於治療各種類型的癌症。因此，隨著癌症負擔的加重，全球對安全有效的抗癌藥物的需求也迅速成長。

市場動態

癌症盛行率的上升、老年人口的成長、對安全有效的抗癌藥物的需求增加、人們對癌症和抗癌藥物認知的提高以及抗癌藥物治療中心數量的增加是預計在預測期內促進全球抗癌藥物市場成長的一些因素。

例如，根據美國癌症協會 (ACS) 的數據，預計到 2023 年，美國將有超過 1,958,310 例新發癌症病例和 609,820 例死亡病例。此外，根據印度醫學研究理事會 (ICMR) 的癌症報告，未來五年印度的癌症病例可能會增加 12%，預計到 2025 年，將有約 15 億人患有這種非傳染性疾病，高於 2020 年的 13.9 億人。

研究的主要特點

本報告對全球腫瘤藥物市場進行了詳細分析，並以 2024 年為基準年，提供了預測期 2025-2032 的市場規模和年複合成長率（CAGR%）。
它還強調了各個領域的潛在商機，並說明了該市場的有吸引力的投資提案矩陣。
它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的重要見解。
全球抗癌藥物市場的主要企業根據以下參數進行分析，例如公司亮點、產品系列、主要亮點、財務表現和策略。
本報告的見解將使負責人和企業經營團隊能夠就未來的產品發布、新興趨勢、市場擴張和行銷策略做出明智的決策。
全球抗癌藥物市場報告迎合了該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進入者和金融分析師。
相關人員可以透過分析全球抗癌藥物市場所使用的各種策略矩陣來促進決策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 178.76 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	7.60%	2032 Value Projection:	USD 298.51 Bn

Cancer is a most lethal disease in which some of the body's cells grow uncontrollably and spread to other parts of the body. Cancer drugs, such as chemotherapy, hormone therapies, targeted cancer drugs, immunotherapy drugs, and bisphosphonates, among others, are used to treat different types of cancer. Thus, with the rise in burden of cancer, the demand for safe and effective cancer drugs is also increasing with a rapid pace, worldwide.

Market Dynamics:

Increasing prevalence of cancer, growing geriatric population, high demand for safe and effective cancer drugs, increasing awareness among people about a cancer and cancer drugs, and increasing number of cancer treatment centres are factors expected to augment the growth of the global cancer drugs market during the forecast period.

For instance, according to the American Cancer Society (ACS), in 2023, more than 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the United States. While, in 2022, around 1.9 Billion new cancer cases and 609,360 cancer deaths were projected to occur in the U.S. Moreover, according to the cancer report by Indian Council of Medical Research (ICMR), India's cancer cases could increase by 12% in the next five years, with around 1.5 Billion people projected to suffer from the non-communicable disease by 2025, up from 1.39 Billion in 2020.

Key features of the study:

This report provides in-depth analysis of the global cancer drugs market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global cancer drugs market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Pfizer Inc., Novartis AG, Merck & Co., Inc., Celgene Corporation, AstraZeneca PLC, Astellas Pharma Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, and Johnson & Johnson (Janssen Global Services, LLC), among others.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global cancer drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cancer drugs market.

Detailed Segmentation:

Global Cancer Drugs Market, By Drug Class Type:
- Chemotherapy
- Targeted Therapy
- Immunotherapy (Biologic Therapy)
- Hormonal Therapy)
Global Cancer Drugs Market, By Indication:
- Lung Cancer
- Stomach Cancer
- Colorectal Cancer
- Breast Cancer
- Prostate Cancer
- Liver Cancer
- Esophagus Cancer
- Cervical Cancer
- Kidney Cancer
- Bladder Cancer
- Other Cancer
Global Cancer Drugs Market, By Geography:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Company Profiles:
- Pfizer Inc.
- Novartis AG
- Merck & Co., Inc.
- Celgene Corporation
- AstraZeneca PLC
- Astellas Pharma Inc.
- AbbVie Inc.
- F. Hoffmann-La Roche Ltd.
- Bristol-Myers Squibb Company
- Johnson & Johnson (Janssen Global Services, LLC)

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Class Type
- Market Snapshot, By Indication
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Increasing burden of cancer across the globe
- Adverse effects of cancer drugs
- Growing demand for safe and effective drugs
Impact Analysis
Key Highlights
Regulatory Scenario
Product launch/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Global Cancer Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Global Cancer Drugs Market, By Drug Class Type, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Targeted Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Immunotherapy (Biologic Therapy)
Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Hormonal Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

6. Global Cancer Drugs Market, By Indication, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Lung Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Stomach Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Colorectal Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Breast Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Prostate Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Liver Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Esophagus Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Cervical Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Kidney Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Bladder Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Other Cancers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

7. Global Cancer Drugs Market, By Region, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032,(US$ Bn)

8. Competitive Landscape

Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Celgene Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AstraZeneca PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Astellas Pharma Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
F. Hoffmann-La Roche Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Johnson & Johnson (Janssen Global Services, LLC)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Analyst Views